AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00984477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of oral suspension
Study NCT00984477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5122
Description: A single intravenous infusion
Study NCT00953667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release Niacin, Extended Release Niacin, Endotoxin
Description: Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
Study NCT00823251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IlluminOss device
Description: The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
Study NCT03011788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely Oral Solution
Description: Bowel purge prior to,colonoscopy
Study NCT01885156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftin 1% Cream
Description: Topically applied once a day
Study NCT01885156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Topically applied once a day
Study NCT02241148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 500mg
Description: 500 mg, tablets every 8 hours
Study NCT02241148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Taping will be changed every week.
Study NCT03117231 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. However, during sham stimulation (placebo) the current will not be active for the full 20 minutes
Study NCT01157676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open radical cystectomy
Description: Standard of care removal of urinary bladder.
Study NCT02663011 — intervention group
Intervention type: OTHER
Intervention: Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin
Description: To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation.
Study NCT03212118 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU-0)
Description: The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees.
Study NCT03212118 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured talks (TAU-2)
Description: Two structured talks (not including elements from motivational interviewing)
Study NCT03212118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing (MI)
Description: Two structured talks (must have a valid motivational interviewing content).
Study NCT00405080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769 (Casopitant) oral tablets
Description: Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
Study NCT00405080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin oral capsules
Description: Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
Study NCT04034706 — intervention group
Intervention type: OTHER
Intervention: DEXA
Description: DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.
Study NCT04034706 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance (MR) Assessment of the Abdomen
Description: Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.
Study NCT04034706 — intervention group
Intervention type: OTHER
Intervention: MR assessment of Whole Body Fat
Description: Volumetric measurement of fat, muscle and bone
Study NCT04034706 — intervention group
Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: 0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.
Study NCT04034706 — intervention group
Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.
Study NCT03782233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
Description: 50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).
Study NCT01157676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic assisted radical cystectomy
Description: Standard of care removal of urinary bladder using DaVinci robot.
Study NCT01157676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DaVinci robot
Description: DaVinci robotic surgical system.
Study NCT03620916 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation, patient controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4, at least 6 hour interval) over next two days
Study NCT03620916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Description: Single dose (0,4 mg) intrathecal morphine immediately before operation, patient-controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4, at least 6 hour interval) over next two days in the postoperative period
Study NCT03782233 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).
Description: 33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).
Study NCT01814527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid
Description: 5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
Study NCT01814527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules that are identical to the treatment.
Study NCT03833492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Underwater EMR
Description: Polypectomy is performed under full water emersion without the use of submucosal injection.
Study NCT01715168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOXIL/CAELYX
Study NCT01715168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-0918
Study NCT04338672 — intervention group
Intervention type: OTHER
Intervention: COVID-19 Pandemic
Description: Exposure: the novel coronavirus disease (Covid-19) outbreak
Study NCT00343265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone gel
Description: Vaginal gel once daily
Study NCT00343265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: once daily
Study NCT03507036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound system
Description: Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
Study NCT00468299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol and placebo
Description: Women in this group receive 800 mcg misoprostol plus a placebo
Study NCT04496531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Neuromodulation Stimulator
Study NCT04496531 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Portable Neuromodulation Stimulator
Study NCT00468299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Description: This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
Study NCT00669890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Dose Escalation
Study NCT00669890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Conditioning Regimen
Study NCT00669890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning Regimen
Study NCT00669890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: (Unrelated Donors only)
Study NCT00669890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: GVHD Prophylaxis
Study NCT00669890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: GVHD Prophylaxis
Study NCT00669890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: GVHD Prophylaxis
Study NCT01562080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Armolipid Plus
Description: one tablet per day during 12 weeks
Study NCT01562080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet per day during 12 weeks
Study NCT03125226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Hydrogel
Description: Given TracelT hydrogel via injection
Study NCT03332459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
Study NCT03332459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
Study NCT02789059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle oxygenation
Description: Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
Study NCT01021735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept or adalimumab
Description: etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
Study NCT01021735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1g x2 by IV infusion repeated every 5 months or more
Study NCT02388581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
Description: Anti-H. pylori Therapy
Study NCT02205996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (Humulin S)
Description: Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
Study NCT02205996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Euglycaemic Hypoglycaemic Insulin clamp
Study NCT04173806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facebook intervention
Description: The intervention consists of the content of the course on telemedicine through a closed group of Facebook according to the established syllabus whose educational material is video classes, discussion forums and online questionnaires. The duration of the course will be 5 weeks, each week two classes will be uploaded to the Facebook platform in succession until the course is completed. So that the student can visualize the content progressively and continuously.
Study NCT04173806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Training:
Description: In this group the participants are exposed to the same course content and perform similar activities as the intervention group on Facebook during the same period but on the Moodle educational platform. The Moodle platform was chosen because it has been widely used in several institutions, with a large user community worldwide, with approximately 50,000 registrations in more than 200 countries and due to the many easy-to-use educational tools it offers. So it is one of the educational platforms that has demonstrated its efficiency in the medical educational field.
Study NCT00408850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 15 mg per day for 6 weeks and 30 mg per day for further 6 weeks
Study NCT00408850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
Study NCT04612725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
Study NCT04612725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo and Benralizumab
Description: 2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
Study NCT04068896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 1
Study NCT04068896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 2
Study NCT04068896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 3
Study NCT04068896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 4
Study NCT04068896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 5
Study NCT04068896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 6
Study NCT04068896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00526292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer cell therapy
Description: The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
Study NCT00526292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
Study NCT00526292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Day -5 fludarabine 25mg/m2 CIV for 5 days
Study NCT03799796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring with Online Peer Support
Description: Hispanic Adults who are Spanish-Speaking with type 2 diabetes who are not using insulin will be asked to use flash glucose monitoring and to sign up for an moderated online peer support group where they can ask questions and share progress.
Study NCT04123522 — intervention group
Intervention type: PROCEDURE
Intervention: anterior approach
Description: anterior approach
Study NCT04123522 — intervention group
Intervention type: PROCEDURE
Intervention: posterior appraoch
Description: posteiror appraoch
Study NCT02314936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litesse powder containing 12 g polydextrose
Description: 12 g polydextrose
Study NCT02314936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litesse powder containing 8 g polydextrose
Description: 8 g polydextrose, 4 g maltodextrin
Study NCT02314936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litesse powder containing 4 g polydextrose
Description: 4 g polydextrose, 8 g maltodextrin
Study NCT02314936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 g Maltodextrin
Study NCT04139655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: Oral colchicine given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
Study NCT04139655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
Study NCT03418155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of TongBi Capsule
Description: TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.
Study NCT03418155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment of TongBi placebo
Description: TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
Study NCT03166982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal approach
Study NCT03166982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic approach
Study NCT04154748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation 90W power
Study NCT04154748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Plasma Coagulation 90W power
Study NCT04154748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Plasma Coagulation 60W power
Study NCT04154748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 120 mg
Study NCT04154748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 120 mg
Study NCT04154748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 40 mg
Study NCT00175019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, tablets, orally, once daily.
Study NCT00175019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 120 mg, tablets, orally, once daily.
Study NCT00175019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
Study NCT00968370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day-care clinic
Description: Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
Study NCT00968370 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hospital Management
Description: Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
Study NCT05701683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri Probiotic
Description: Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy
Study NCT03396133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Snap
Description: screen, transmission, and analysis ECG automated